Top Markets
#1 Islamic Coin Islamic Coin +152.50%
#2 Bitway Bitway +42.48%
#3 Starpower Starpower +38.69%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +33.29%
#5 aelf aelf +28.49%
#6 Pons Pons +26.56%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.55%
#8 SkyAI SkyAI +19.30%
#9 Ocean Protocol Ocean Protocol +16.33%
#10 Bedrock Bedrock +15.75%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Rank in Stocks #29675
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Share Price
$0.20877985
Market Cap
$20.11M
Change (1 day)
-3.03%
Change (1 year)
-66.13%
Country
JP
Trade Modalis Therapeutics Corporation (4883)

Category

Healthcare
P/E ratio for Modalis Therapeutics Corporation (4883)
P/E ratio as of 2026 TTM: 0
According to Modalis Therapeutics Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Modalis Therapeutics Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.